Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas June 28, 20230CommentsEN NL Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC June 23, 20230CommentsEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas June 22, 20230CommentsEN NL Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC June 16, 20230CommentsEN NL Read More
Oxurion Issues EUR 1.0 million in Bonds for Tranche 3 of the Funding Program with Atlas Special Opportunities LLC June 15, 20230CommentsEN Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas June 15, 20230CommentsEN NL Read More
Oxurion Finalizes Enrollment in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema June 12, 20230CommentsEN Read More
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC June 12, 20230CommentsEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS June 9, 20230CommentsEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS June 6, 20230CommentsEN NL Read More
Oxurion Announces Results of the Extraordinary Shareholders’ Meeting of 22 May 2023 June 5, 20230CommentsEN NL Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC June 1, 20230CommentsEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS May 31, 20230CommentsEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS May 26, 20230CommentsEN NL Read More
Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema May 25, 20230CommentsEN Read More
